The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors

The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment

(2018) Pricivel M. Carrera et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Keeping Expectations in Check With Immune Checkpoint Inhibitors

(2018) Jennifer S. Temel et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

(2018) Margaret K. Callahan et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

(2018) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy

(2018) David Levy et al.   SUPPORTIVE CARE IN CANCER

Health-related quality of life results from the phase III CheckMate 067 study

(2017) Dirk Schadendorf et al.   EUROPEAN JOURNAL OF CANCER

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

(2017) Dirk Schadendorf et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

(2016) G. V. Long et al.   ANNALS OF ONCOLOGY

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial:

(2016) F. Stephen Hodi et al.   CANCER RESEARCH

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

(2016) Dirk Schadendorf et al.   EUROPEAN JOURNAL OF CANCER

Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial

(2016) Mbathio Dieng et al.   JOURNAL OF CLINICAL ONCOLOGY

Financial Hardship Associated With Cancer in the United States: Findings From a Population-Based Sample of Adult Cancer Survivors

(2016) K. Robin Yabroff et al.   JOURNAL OF CLINICAL ONCOLOGY

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Scan-associated distress in lung cancer: Quantifying the impact of “scanxiety”

(2016) Joshua M. Bauml et al.   LUNG CANCER

Systematic review of psychosocial outcomes for patients with advanced melanoma

(2016) Jeff Dunn et al.   PSYCHO-ONCOLOGY

Symptom Burden and Quality of Life among Women with HER2+Metastatic Breast Cancer

(2015) Musa Mayer et al.   Breast Journal

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

(2015) Dirk Schadendorf et al.   EUROPEAN JOURNAL OF CANCER

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

(2015) Jean Jacques Grob et al.   LANCET ONCOLOGY

Cross-cultural development of a quality-of-life measure for patients with melanoma

(2015) Julie B. Winstanley et al.   MELANOMA RESEARCH

Survivorship care plans in cancer: a systematic review of care plan outcomes

(2014) M E Brennan et al.   BRITISH JOURNAL OF CANCER

Summing it up: An integrative review of studies of cancer survivorship care plans (2006-2013)

(2014) Deborah K. Mayer et al.   CANCER

What are the pertinent quality-of-life issues for melanoma cancer patients? Aiming for the development of a new module to accompany the EORTC core questionnaire

(2013) Julie B. Winstanley et al.   MELANOMA RESEARCH

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

(2012) Dennis A Revicki et al.   Health and Quality of Life Outcomes

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Fear of recurrence and disease progression in long-term (≥5 years) cancer survivors-a systematic review of quantitative studies

(2012) L. Koch et al.   PSYCHO-ONCOLOGY

Validation of the Supportive Care Needs Survey-short form 34 with a simplified response format in men with prostate cancer

(2011) Penelope Schofield et al.   PSYCHO-ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Social Difficulties Inventory (SDI): development of subscales and scoring guidance for staff

(2010) Penny Wright et al.   PSYCHO-ONCOLOGY

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer Therapy-Melanoma questionnaire

(2008) Janice N. Cormier et al.   CANCER